Treatment of Weight Gain with Fluoxetine in Olanzapine-Treated Schizophrenic Outpatients
Open Access
- 14 October 2002
- journal article
- clinical trial
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (3) , 527-529
Abstract
Significant weight gain is a side effect associated with olanzapine treatment in some patients. We investigated the efficacy of high-dose fluoxetine as a weight-reducing agent for patients who develop early weight gain with olanzapine treatment. Patients that gained ⩾ 3% of their baseline weight in the initial 8 weeks of olanzapine treatment (n=31) were randomized to double-blind treatment with placebo or fluoxetine (60 mg/day). Clinical, weight, and weight-related measures were assessed. Fluoxetine failed to demonstrate weight-reducing effects (fluoxetine group: baseline mean 80.5 kg, SD=19.1, last mean=83.5 kg, SD=19.8; placebo group: baseline mean=77.1 kg, SD=12.1, last mean=78.8 kg, SD=10.6; F=1.3; df=1, 18; p=0.3). There were no differential effects in psychopathology, extrapyramidal side effects or weight-related measures between the placebo and fluoxetine groups. Serotonin reuptake inhibitors are probably not a practical option to counteract weight gain induced by atypical antipsychotics. Atypical-induced weight gain may result from mechanisms other than 5HT reuptake blockade.Keywords
This publication has 11 references indexed in Scilit:
- Olanzapine-Induced Weight Gain in Patients With First-Episode Schizophrenia: A Double-Blind, Placebo-Controlled Study of Fluoxetine AdditionAmerican Journal of Psychiatry, 2002
- Long-Term Olanzapine TreatmentThe Journal of Clinical Psychiatry, 2001
- Antipsychotic-Induced Weight Gain: A Comprehensive Research SynthesisAmerican Journal of Psychiatry, 1999
- Lipid Research Clinics QuestionnaireMedicine & Science in Sports & Exercise, 1997
- Prospects for pharmacotherapy of schizophreniaThe Lancet, 1995
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced ObesityThe British Journal of Psychiatry, 1988
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960